Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Investors breathed a sign of relief as multiple pipeline assets from Celgene closed the year with positive updates.

Here's Why Bristol-Myers Squibb Jumped 12.7% in December

Does Bristol-Myers Squibb (BMY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Bristol-Myers Squibb (BMY) is a Great Choice

AbbVie

Amgen

Anavex Life Sciences

MannKind

Pfizer

Vertex Pharmaceuticals

Each year, MoneyShow asks the nation’s leading financial newsletter advisors for their favorite stocks for the coming year. Here are seven favorites from the pharmaceutical and biotechnology space.

7 Hot Drug Stocks To Buy In 2020

Biogen

Gilead Sciences

Drug manufacturers across the globe raised the list prices of more than 250 therapies on New Year’s Day, according to aggregate reports from Reuters and research firm 3 Axis Advisors.

Drugmakers Kick Off 2020 With Margin-Expanding Price Hikes

Arcosa Inc

Best Buy

Top Ranked Momentum Stocks to Buy for January 2nd

Canopy Growth

Cronos Group

Options trading was hot in Bristol-Myers Squibb, Cronos and Canopy Growth stock on Tuesday. Here’s what the data suggests moving forward.

Thursday’s Vital Data: Bristol-Myers Squibb, Cronos and Canopy Growth

Amazon

Broadcom

Brookfield Asset Management

Innovative Industrial Properties

5 Stocks I'm Buying For My Retirement Portfolio In 2020

Happy New Year … hope you don’t need a prescription in 2020.

Big Pharma raises prescription drug prices on New Year’s Day

Drugmakers including Bristol-Myers Squibb, Gilead Sciences, and Biogen hiked U.S. list prices on more than 50 drugs on Wednesday.

Bristol-Myers, Gilead, and Biogen hike US drug prices as the new year begins

GlaxoSmithKline

Sanofi

Drugmakers including Bristol-Myers Squibb Co, Gilead Sciences Inc, and Biogen Inc hiked U.S. list prices on more than 50 drugs on Wednesday, bringing total New Year's Day drug price increases to more than 250, according to data analyzed by healthcare research firm 3 Axis Advisors.

More drugmakers hike U.S. prices as new year begins

Home Depot

Merck

NIKE

Texas Instruments

Bristol-Myers Squibb, Merck, The Home Depot, Texas Instruments, and Nike could be strong dividend plays into the new year.

Best Dividend Stocks for January 2020

Target

Finance is simply human behavior. We all have different perspectives, especially when it comes to financial markets.

After 20 Years Of Trading, You Learn That You Actually Know Nothing

Bristol-Myers (BMY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Bristol-Myers (BMY) Stock Might be a Great Pick

Celgene

One of my better investments of 2019 was Celgene (NASDAQ:CELG), which was acquired by Bristol-Myers (NYSE:BMY).

An Unusual Investment With 125% Upside

Apollo Investment

American Outdoor Brands

Top Ranked Momentum Stocks to Buy for December 26th

Eli Lilly

Teva Pharmaceutical

Keep in mind that short sellers betting against big pharma are taking on an added risk.

Big Pharma Short Sellers Get Selective

2 Pharmaceutical Companies Offering Above-Average Dividend Growth

The EC approves Bristol-Myers' (BMY) Revlimid in combination with Rituxan for the treatment of previously-treated FL (Grade 1-3a).

Bristol-Myers' Revlimid Combo Gets EU Nod for New Indication

B2Gold

FUJIFILM Holdings Corp

H&R Block

PBF Logistics

There are chances that some of the underperforming stocks of 2019 might rebound in 2020 given the favorable factors and their fundamental strength.

2019 Was a Tough Year but These 5 Stocks May Rebound in 2020

But the big biotech isn't a happy camper about its contribution.

How Gilead Sciences Is Helping Fund Bristol-Myers Squibb's Celgene Acquisition

Bristol-Myers Squibb: 2020 Total Return Play With A 2.8% Dividend Yield

bluebird bio

Forty Seven Inc

Johnson & Johnson

uniQure

The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.

The Top Biotech Stocks to Watch Following ASH 2019

Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.

Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 19, 2019

Installed Building Products

Intel

NuVasive

When a broker upgrades a stock, you can rely on their judgment. Nonetheless, you should also take into account few other factors to ensure steady returns.

Buy These 5 Stocks With Upgraded Broker Ratings for 2020

Integer Holdings

Medtronic

Synaptics

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

News for Bristol-Myers Stock (BMY)